Hanson Wade는 신약개발·바이오파마 업계를 위한 전문 콘퍼런스와 R&D 시장정보 서비스를 결합해 제공하는 영국 기반 라이프 사이언스 정보/이벤트 기업으로, 

신약개발(R&D) 분야에 특화된 B2B 콘퍼런스 기획·운영이 핵심 사업으로, ADC(항체약물접합체), 자가면역/면역학, 세포치료제 등 세분화된 최신 R&D 영역을 다루는 200여 개 이상의 콘퍼런스·커뮤니티를 운영하며 연간 2만5천~3만 명 이상의 바이오파마 고객을 지원하고 있습니다.

올 하반기 한국에서 열리는 3개 컨퍼런스 행사에 대해 소개드리오니 내용 참고하시어 관심이 있으신 분들은 많은 참가 신청 바랍니다. 

KDDF 주관연구개발기관은 하기 컨퍼런스 참가 등록 시 10% 할인 혜택을 받으실 수 있습니다. 

등록을 완료하시기 전에 KDDF 사업화지원팀 (kddf_bd@kddf.org)로 할인 프로모션 코드를 요청해 주시기 바랍니다.

2nd World RNA-Based Therapeutics & Vaccines Summit South Korea  Lean more

10 - 12 November, 2026
Incheon, South Korea

In Person, Presentations in English 

Summary of Event: 

Developing Safe & Efficacious mRNA, CircRNA & SaRNA Medicines With Smarter Design Optimization, Targeted Delivery & Scalable Manufacturing for Clinical & Commercial Readiness

Bringing 90+ key experts from South Korea, China, Japan, Australia and more to share insights and forge collaborations to advance cutting-edge mRNA design, therapeutic pipeline advancements, targeted delivery breakthroughs, and bring solutions to the manufacturing and analytical challenges limiting scale and speed.

Top Speakers & Sessions: 

- Optimizing mRNA sequence design and manufacturing of circular RNA modalities to superior functional validation with insights from Circurna, RZnomics and National Taiwan University
- Advancing mRNA & LNP platform technologies to achieve clinical success in vivo CAR and widen the therapeutic barriers, with key progress updates from Abogen Biosciences, Breeze Bio and Medici Bio

- Overcome the challenges of small-scale design to GMP manufacturing capability for the personalized cancer vaccines and their potential marketability through shared discussions with LG Chem and Aston Sci

- Gain practical strategies for accelerating mRNA process, quality control and regulatory alignment strategies across APAC to ensure scalability and cost-effectiveness across development with insights from Meiji Seika Pharma and RNA Australia

- Achieve the best LNP composition and platform to ensure organ-specific targeting, tolerability and safety with key academic insights from Tel-Aviv University, Yeungnam University and Seoul National University

World CNS Summit South Korea Learn more

8-10 December 2026
Incheon, South Korea

In Person, Presentations in English

 Summary of Event:

Advance Disease-Modifying Targets, Revolutionize BBB Delivery & Collaborate with Global Partners to Power the Next Frontier of Neuroscience Therapeutics in Korea

Connecting Korean biopharma with international leaders from across China, Japan, India, US and Europe to collaboratively drive innovation in targeted, mechanism-differentiated therapies for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders.

Agenda Highlights:

• Takeda, Novartis, J&J and Eli Lilly representatives will share what they are seeking when evaluating the emerging Korean landscape of novel CNS targets and modalities.
• ABL Bio will present on IGF1R-mediated transcytosis and distinct endocytic pathways to enable robust BBB transport in APOE4 genotype populations.
• AriBio will share lessons from out-licensing ARI1001 to Fosun Pharma at Phase III, including navigating regulatory and geopolitical friction to streamline collaboration.
• Sovargen, Rznomics and Angelini Pharma will discuss emerging RNA editing, RNAi and ASO technologies to access undruggable CNS targets.
• ADEL, Brainimmunex, Mthera Pharma and JCR Pharmaceuticals with present brand-new data on innovative programs encompassing proteasome activation, metabolic reprogramming of microglia, and BBB delivery of AOCs.

 World Novel Drug Discovery Summit South Korea Learn more

8-10 December 2026
Incheon, South Korea

In Person, Presentations in English

Summary of Event:

Accelerating Future Best-in-Class Platforms for Next-Generation Modalities by Integrating AI for Smarter, Faster & De-Risked Drug Discovery

Join 100+ drug discovery enthusiasts, from strategic decision-makers to hands-on technical experts across Korean innovators, global pharma leaders and industry-leading service providers to discover how integrating AI into drug discovery can accelerate development of best-in-class platforms for novel modalities across ADCs, PROTACs, peptides and vaccines for improved positioning for global partnering and out-licensing opportunities. 

Agenda Highlights:

• Unlock leading pharma approaches to leverage AI/ML tools to accelerate and enhance drug discovery workflows with Eli Lilly, Hanmi Pharm and Sanofi
• Leverage multi-omics analysis to unlock insights into novel target discovery and mechanistic characterization with AIGEN Sciences, Degron Therapeutics and Seoul National University
• Uncover training, validation, and iterative feedback of in silico and generative AI platforms for de novo discovery with AIGEN Drug, CardiaTec and ONCROCROSS
• Uncover Pan-modality case studies utilizing structural biology, biophysics and computational workflows to develop ADC, vaccine, peptide and induced proximity modalities with Aston Sci, Innovent Biologics and Portrai

※ KDDF는 해당 프로그램의 직접 운영 주체가 아니며, 협력사 및 유관기관의 주요 프로그램을 홍보·소개하여 국내 신약개발 연구자들에게 유용한 정보를 제공하고자 합니다.